Ekso Bionics Holdings, Inc. (EKSO)
USD 0.36
(-1.55%)
USD 0.36
(-1.55%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.31 Million USD | 5.5% |
| 2022 | 15.46 Million USD | 29.41% |
| 2021 | 11.94 Million USD | -26.08% |
| 2020 | 16.16 Million USD | 6.91% |
| 2019 | 15.11 Million USD | 1.28% |
| 2018 | 14.92 Million USD | -10.06% |
| 2017 | 16.59 Million USD | -7.25% |
| 2016 | 17.89 Million USD | -23.5% |
| 2015 | 23.39 Million USD | 119.13% |
| 2014 | 10.67 Million USD | 75473.49% |
| 2013 | 14.12 Thousand USD | 74.37% |
| 2012 | 8100.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 14.33 Million USD | -3.93% |
| 2024 Q2 | 14.92 Million USD | 0.13% |
| 2024 Q1 | 14.9 Million USD | -8.62% |
| 2023 Q2 | 16.17 Million USD | 2.26% |
| 2023 Q4 | 16.31 Million USD | 2.42% |
| 2023 FY | 16.31 Million USD | 5.5% |
| 2023 Q1 | 15.82 Million USD | 2.33% |
| 2023 Q3 | 15.92 Million USD | -1.56% |
| 2022 Q1 | 10.75 Million USD | -9.97% |
| 2022 Q4 | 15.46 Million USD | 44.54% |
| 2022 Q3 | 10.69 Million USD | 21.68% |
| 2022 FY | 15.46 Million USD | 29.41% |
| 2022 Q2 | 8.79 Million USD | -18.27% |
| 2021 Q4 | 11.94 Million USD | 2.36% |
| 2021 Q1 | 15.52 Million USD | -3.92% |
| 2021 FY | 11.94 Million USD | -26.08% |
| 2021 Q3 | 11.67 Million USD | -9.37% |
| 2021 Q2 | 12.87 Million USD | -17.08% |
| 2020 Q3 | 15.08 Million USD | -32.59% |
| 2020 Q2 | 22.37 Million USD | 91.0% |
| 2020 FY | 16.16 Million USD | 6.91% |
| 2020 Q4 | 16.16 Million USD | 7.15% |
| 2020 Q1 | 11.71 Million USD | -22.5% |
| 2019 Q4 | 15.11 Million USD | 8.99% |
| 2019 FY | 15.11 Million USD | 1.28% |
| 2019 Q3 | 13.87 Million USD | -31.26% |
| 2019 Q2 | 20.17 Million USD | 23.6% |
| 2019 Q1 | 16.32 Million USD | 9.37% |
| 2018 Q2 | 15.58 Million USD | -3.34% |
| 2018 Q1 | 16.12 Million USD | -2.87% |
| 2018 Q4 | 14.92 Million USD | -11.34% |
| 2018 FY | 14.92 Million USD | -10.06% |
| 2018 Q3 | 16.83 Million USD | 8.05% |
| 2017 Q4 | 16.59 Million USD | 20.81% |
| 2017 Q1 | 18.27 Million USD | 2.15% |
| 2017 Q3 | 13.73 Million USD | -20.61% |
| 2017 FY | 16.59 Million USD | -7.25% |
| 2017 Q2 | 17.3 Million USD | -5.33% |
| 2016 Q1 | 15.79 Million USD | -32.46% |
| 2016 Q2 | 12.01 Million USD | -23.95% |
| 2016 Q4 | 17.89 Million USD | 33.61% |
| 2016 Q3 | 13.39 Million USD | 11.48% |
| 2016 FY | 17.89 Million USD | -23.5% |
| 2015 Q3 | 12.88 Million USD | -0.7% |
| 2015 Q2 | 12.97 Million USD | 18.61% |
| 2015 Q1 | 10.93 Million USD | 2.45% |
| 2015 FY | 23.39 Million USD | 119.13% |
| 2015 Q4 | 23.39 Million USD | 81.6% |
| 2014 Q4 | 10.67 Million USD | -49.98% |
| 2014 Q2 | 36.7 Million USD | -61.9% |
| 2014 Q1 | 96.33 Million USD | 610052.89% |
| 2014 FY | 10.67 Million USD | 75473.49% |
| 2014 Q3 | 21.34 Million USD | -41.86% |
| 2013 Q2 | 10.07 Thousand USD | -28.67% |
| 2013 Q4 | 15.78 Thousand USD | 56.73% |
| 2013 FY | 14.12 Thousand USD | 74.37% |
| 2013 Q1 | 14.12 Thousand USD | -23.78% |
| 2013 Q3 | 10.07 Thousand USD | 0.0% |
| 2012 Q2 | 9781.00 USD | 0.0% |
| 2012 FY | 8100.00 USD | 0.0% |
| 2012 Q4 | 18.53 Thousand USD | 0.0% |
| 2012 Q3 | 18.53 Thousand USD | 89.46% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | 87.115% |
| AngioDynamics, Inc. | 112.08 Million USD | 85.447% |
| AtriCure, Inc. | 147.76 Million USD | 88.961% |
| Avinger, Inc. | 19.97 Million USD | 18.326% |
| Azenta, Inc. | 351.22 Million USD | 95.356% |
| BioLife Solutions, Inc. | 75.05 Million USD | 78.265% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 99.603% |
| Daxor Corporation | 858.75 Thousand USD | -1799.487% |
| Femasys Inc. | 9.4 Million USD | -73.472% |
| GlucoTrack, Inc. | 1.7 Million USD | -855.035% |
| Harvard Bioscience, Inc. | 64.29 Million USD | 74.628% |
| Hologic, Inc. | 4.02 Billion USD | 99.595% |
| ICU Medical, Inc. | 2.25 Billion USD | 99.277% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 99.202% |
| KORU Medical Systems, Inc. | 8.1 Million USD | -101.204% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | 66.627% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -2371.755% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -2371.755% |
| Masimo Corporation | 1.67 Billion USD | 99.027% |
| Microbot Medical Inc. | 3.82 Million USD | -326.346% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | 34.954% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | 98.548% |
| Nephros, Inc. | 3.5 Million USD | -365.658% |
| NovoCure Limited | 783.63 Million USD | 97.918% |
| NEXGEL, Inc. | 4.78 Million USD | -240.614% |
| NEXGEL, Inc. | 4.78 Million USD | -240.614% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | 81.134% |
| OraSure Technologies, Inc. | 52.17 Million USD | 68.735% |
| Pro-Dex, Inc. | 23.34 Million USD | 30.12% |
| Pulse Biosciences, Inc. | 16.44 Million USD | 0.803% |
| Predictive Oncology Inc. | 6.14 Million USD | -165.431% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | -138.313% |
| QuidelOrtho Corporation | 3.55 Billion USD | 99.541% |
| Repligen Corporation | 853.2 Million USD | 98.088% |
| Sanara MedTech Inc. | 29.28 Million USD | 44.296% |
| STAAR Surgical Company | 102.73 Million USD | 84.123% |
| Sharps Technology, Inc. | 3.85 Million USD | -323.141% |
| Utah Medical Products, Inc. | 7.14 Million USD | -128.3% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 99.6% |
| Jin Medical International Ltd. | 8.92 Million USD | -82.781% |